BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
July 17, 2024 07:00 ET | BioCardia, Inc.
SUNNYVALE, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
June 07, 2024 07:00 ET | BioCardia, Inc.
BioCardia announces that the USPTO has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a 2036 expiration date.
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan
June 08, 2023 07:00 ET | BioCardia, Inc.
SUNNYVALE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies
April 04, 2023 07:00 ET | BioCardia, Inc.
SUNNYVALE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...